Jeff Yass’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,812
| Closed | -$64.8K | – | 13094 |
|
|
2024
Q4 | $64.8K | Sell |
1,812
-60
| -3% | -$3.1K | ﹤0.01% | 11574 |
|
|
2024
Q3 | $88.5K | Buy |
1,872
+1,256
| +204% | +$55.4K | ﹤0.01% | 11123 |
|
|
2024
Q2 | $31K | Sell |
616
-4,828
| -89% | -$349K | ﹤0.01% | 11553 |
|
|
2024
Q1 | $610K | Buy |
+5,444
| New | +$541K | ﹤0.01% | 8036 |
|
|
2023
Q3 | – | Sell |
-4,856
| Closed | -$399K | – | 12600 |
|
|
2023
Q2 | $399K | Buy |
4,856
+3,600
| +287% | +$527K | ﹤0.01% | 8837 |
|
|
2023
Q1 | $129K | Buy |
+1,256
| New | +$176K | ﹤0.01% | 11057 |
|
|
2021
Q3 | – | Sell |
-3,816
| Closed | -$1.3M | – | 13251 |
|
|
2021
Q2 | $1.3M | Sell |
3,816
-2,048
| -35% | -$775K | ﹤0.01% | 7036 |
|
|
2021
Q1 | $2.37M | Buy |
5,864
+5,356
| +1,054% | +$2.6M | ﹤0.01% | 5501 |
|
|
2020
Q4 | $338K | Sell |
508
-4,720
| -90% | -$2.62M | ﹤0.01% | 9037 |
|
|
2020
Q3 | $2.43M | Buy |
5,228
+4,232
| +425% | +$2.14M | ﹤0.01% | 4249 |
|
|
2020
Q2 | $583K | Buy |
996
+596
| +149% | +$204K | ﹤0.01% | 7042 |
|
|
2020
Q1 | $58K | Buy |
+400
| New | +$69.9K | ﹤0.01% | 9606 |
|
Other funds holding MRSN
Jeff Yass's MRSN Position: Q3 2025 in Review
Jeff Yass sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 17,975 shares — an estimated $133K sold.
Jeff Yass first reported a position in MRSN in Q2 2019 and held it in 24 quarters. The position peaked at $2.13M in Q1 2021. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.
- Jeff Yass reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
- Jeff Yass sold 17,975 Mersana Therapeutics shares in Q3 2025, an estimated $133K.
- Jeff Yass first reported a position in Mersana Therapeutics in Q2 2019 and held it in 24 quarters.
- Jeff Yass's Mersana Therapeutics position peaked at $2.13M in Q1 2021.
- 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.